enGene Therapeutics Inc. (ENGN)
NASDAQ (CM) NASDAQ (CM) Primary 
XFRA Summary
enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path
enGene NASDAQ: ENGN used a company webinar to outline preclinical findings for its investigational non-viral gene therapy, detalimogene voraplasmid, used with a polidocanol surfactant bladder rinse, while community urologists discussed the treatment burden facing patients with high-risk non-muscle invasive bladder cancer, or NMIBC.
enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market
enGene Therapeutics remains deeply undervalued, trading below its $3.97/share cash position despite pipeline and execution risks. ENGN's lead asset, detalimogene voraplasmid, faces FDA approval risk due to weak 12-month durability, but management is pursuing a surfactant cohort to address efficacy. Cost-saving measures, including a 50% workforce reduction, extend ENGN's cash runway into 2029, supporting operations through pivotal BLA milestones.
enGene Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 13,992 | $24,206 | $23,926.32 | -$279.68 | -1.16% |
 Ilko Menkov Vestal Point Capita LLP | 1.67M | $2.88M | $2.78M | -$108,383.12 | -3.76% |
 Christopher C. Powers Farther Finance Advisors, LLC | 100 | $173 | $156 | -$17 | -9.83% |
 David Vollmer PFS Partners, LLC | 11,000 | $19,030 | $18,260 | -$770 | -4.05% |
 Raymond Debbane Siren, L.L.C. | 6.26M | $10.82M | $10.7M | -$125,133.24 | -1.16% |
enGene Therapeutics Inc. (ENGN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has enGene Therapeutics Inc. ever had a stock split?
enGene Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ronald H. W. Cooper CEO | NASDAQ (CM) Exchange | 29286X101 CUSIP |
| CA Country | 82 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
enGene Holdings Inc. stands as a vanguard in the sector of biotechnological advancements, focusing its efforts through its subsidiary, enGene, Inc. This clinical-stage biotechnology company has dedicated itself to the development of genetic medicines, emphasizing the targeted delivery of therapeutics to mucosal tissues alongside other vital organs. Incorporated in 2023, enGene Holdings Inc. anchors its operations in Saint-Laurent, Canada, symbolizing a blend of innovative research and steadfast dedication towards addressing some of the most challenging medical conditions faced today.
Products and Services
EG-70 (detalimogene voraplasmid)
This product represents enGene Holdings Inc.'s forefront in its array of offerings, manifesting as a cutting-edge, non-viral immunotherapy. Targeted towards patients suffering from non-muscle invasive bladder cancer, particularly those with carcinoma-in-situ (Cis) who have not responded to the traditional Bacillus Calmette-Guérin treatment, EG-70 stands as a testament to the company's innovative strides in genetic medicine. This lead product candidate epitomizes the company's ambition to revolutionize the treatment landscape for a niche yet significantly impacted patient demographic.
Contact Information
